Latest news with #BrighamHyde
Business Wire
18 hours ago
- Health
- Business Wire
Atropos Health Partners with Databricks to Accelerate Evidence Generation and Advance Precision Medicine in Healthcare
PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in translating real-world clinical data into personalized real-world evidence (RWE) and insights, and Databricks, the Data and AI company, today announced a partnership to advance precision medicine for healthcare and life sciences organizations. By building on the Databricks Data Intelligence Platform and leveraging Delta Sharing, Atropos Health empowers clinicians and researchers to generate actionable, evidence-based insights to accelerate drug discoveries and reduce the time from symptom to treatment. Atropos Health utilizes Delta Sharing to access and link datasets across the Atropos Evidence™ Network, the largest federated data network in healthcare with over 300M patient records, including oncology data. Delta Sharing is Databricks' open source approach that enables customers to share live data across platforms, clouds and regions with strong security and governance. The new partnership combines Atropos Health's deep expertise in real-world evidence generation with Databricks' data intelligence expertise. "Turning data into actionable evidence rapidly and accurately will accelerate the pace of innovation in healthcare,' said Dr. Brigham Hyde, CEO and co-founder at Atropos Health. "By responsibly and compliantly linking massive data sets in healthcare, we will drive not only better outcomes for patients, but a seamless user experience for healthcare researchers and providers." 'As we continue to help healthcare and life sciences organizations unlock the power of data intelligence, we're excited to welcome Atropos Health to the Built on Databricks Partner Program. Databricks is invested in bringing the best technology solutions to market for every industry, and this includes working with partners like Atropos Health,' said Michael Sanky, VP of Healthcare & Life Sciences GTM at Databricks. 'Atropos Health exemplifies the transformative potential of building on Databricks, and it's incredible to watch its adoption among healthcare and life sciences organizations who are excited to harness the full power of their data.' Atropos Health recently launched Nodal Patient Deidentification and Query Time Interval Encoding across the GENEVA OS™ platform for members of the Atropos Evidence Network. The addition of Nodal Deidentification to the GENEVA OS platform enables users to fill data gaps in patients longitudinal records from participating Atropos Evidence Network sources, ensuring the most robust deidentified patient records while maintaining data possession and security. Through this partnership, Atropos Health and Databricks are unlocking new opportunities in healthcare and life sciences by providing GENEVA OS™ and the Atropos Evidence™ Network as a single solution for data and analytics, combining Atropos Health's deep expertise in RWE with Databricks' data intelligence expertise. Customers rely on Atropos Health's portfolio of evidence-generation tools through the federated installation of GENEVA OS in their internal cloud data environment. About Atropos Health Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence. To learn more about Atropos Health, visit or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.
Business Wire
28-04-2025
- Business
- Business Wire
Atropos Health Expands Oncology MultiModal Network in the Atropos Evidence Network with Addition of Ontada
PALO ALTO, Calif.--(BUSINESS WIRE)-- Atropos Health, a leader in transforming clinical real-world data (RWD) into personalized real-world evidence (RWE) and insights, has announced a strategic collaboration with Ontada®, a McKesson business and leader in community oncology RWD, clinical education, and point-of-care technologies. This collaboration will enhance the use cases for clinicians, researchers, and healthcare leaders to design care protocols, advance precision medicine and develop new treatments in oncology. Atropos Health's automation tools generate evidence from a customer's own data, via the installation of GENEVA OS™ into customers' internal cloud data environment and the Atropos Evidence™ Network, the largest federated data network in healthcare with over 300 million patient records. As members run queries on the RWD in the Atropos Evidence Network, they have access to the right data for each question, evaluated by the Real-World Fitness Score®. "The demand for high-quality data in oncology is ever present," said Dr. Brigham Hyde, CEO and co-founder of Atropos Health. "The Atropos Evidence™ Network, which will now include Ontada's RWD, includes benefits across the entire healthcare ecosystem. For health systems, the oncology multi-modal network contains the high quality RWD necessary to generate the RWE needed for high-stakes clinical decisions. This collaboration with Ontada will help life sciences organizations accelerate the rate at which RWE insights drive decision-making for drug discovery and development and ensure they are presented and acted upon, driving innovation and ultimately improving the lives of cancer patients." Ontada provides unique insights into the community oncology landscape, where approximately 85% of cancer patients are treated. Its proprietary database, iKnowMed®, is sourced in part from The US Oncology Network, a leading community oncology physician network. The US Oncology Network treats more than 1.4 million cancer patients annually. Ontada's RWD offers comprehensive insights throughout the patient journey and provides a unique view of community cancer care, representing data from more than 2.4 million patients across more than 80 tumor types. "Ontada and Atropos Health are committed to accelerating evidence generation to drive better outcomes for patients with cancer," said Christine Davis, President of Ontada. "This collaboration will empower life sciences organizations by enhancing their evidence-generation capabilities and supporting more effective clinical decision-making that can help to improve patient care." This collaboration comes on the heels of Atropos Health's recent announcement of Federated Nodal Deidentification Technology. The new technology will be added to the GENEVA OS™ platform, available to all Atropos Evidence™ Network members. Longitudinal patient records provide a more complete view of a patient journey. About Atropos Health Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence. To learn more about Atropos Health, visit or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.
